Loading...
Loading...
TG Therapeutics, Inc.
, today announced that clinical data for TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, the Company's once-daily PI3K delta inhibitor, will be presented at the 20th Congress of the European Hematology Association (EHA), being held from June 11 - June 14, 2015 in Vienna, Austria as well as at the 13th International Congress on Malignant Lymphoma (ICML), being held from June 17 - June 20, 2015 in Lugano, Switzerland.
The Company and its study investigators will present data from the following clinical studies:
TGR-1202 as a single agent in relapsed/refractory B-cell malignancies
TGR-1202 in combination with TG-1101 ("1303 combination") in CLL and NHL
TGR-1202 + TG-1101 + ibrutinib in B-cell malignancies
TG-1101 in combination with ibrutinib in patients with relapsed/refractory CLL
Additional information on the presentations can be found below:
20th Congress of EHA (Vienna):
Date/Time: Friday, June 12, 2015, 17:15 - 18:45 CEST
Abstract Number: P327 (Poster)
Presentation Title: UBLITUXIMAB + TGR-1202 DEMONSTRATES ACTIVITY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NHL AND HIGH-RISK CLL
Presenter: Matthew Lunning, DO, University of Nebraska, Omaha, NE
Date/Time: Saturday, June 13, 2015, 11:45 – 12:00 CEST
Abstract Number: S432 (Oral Presentation)
Presentation Title: TGR-1202, A NOVEL ONCE DAILY PI3K-DELTA INHIBITOR, DEMONSTRATES CLINICAL ACTIVITY WITH A FAVORABLE SAFETY PROFILE, LACKING HEPATOTOXICITY, IN PATIENTS WITH CLL AND B-CELL LYMPHOMA
Presenter: Owen A. O'Connor, MD, PhD, Columbia Presbyterian Lymphoma Center, New York, NY
ICML Meeting (Lugano):
Date/Time: Wednesday, June 17, 2015, 17:45 CEST
Abstract Number: 038 (Oral Presentation)
Presentation Title: TGR-1202, A NOVEL ONCE DAILY PI3K δ INHIBITOR, DEMONSTRATES CLINICAL ACTIVITY WITH A FAVORABLE SAFETY PROFILE, LACKING HEPATOTOXICITY IN PATIENTS WITH CLL AND B-CELL LYMPHOMA
Presenter: Owen A. O'Connor, MD, PhD, Columbia Presbyterian Lymphoma Center, New York, NY
Date/Time: Thursday, June 18, 2015, 17:15 CEST
Abstract Number: 105 (Oral Presentation)
Presentation Title: UBLITUXIMAB (TG-1101), A NOVEL GLYCOENGINEERED ANTI-CD20 MAB, IN COMBINATION WITH IBRUTINIB ACHIEVES 95% ORR IN PATIENTS WITH HIGHRISK RELAPSED/REFRACTORY CLL
Presenter: John Burke, MD, Rocky Mountain Cancer Center/US Oncology, Aurora, CO
Date/Time: Thursday, June 18, 2015, 17:25 CEST
Abstract Number: 106 (Oral Presentation)
Presentation Title: THE CHEMOTHERAPY-FREE TRIPLET OF UBLITUXIMAB, TGR-1202, AND IBRUTINIB IS SAFE AND HIGHLY ACTIVE IN RELAPSED B-CELL MALIGNANCIES
Presenter: Loretta Nastoupil, MD, MD Anderson Cancer Center, Houston, TX
Date/Time: Thursday, June 18, 2015
Abstract Number: 284 (Poster)
Presentation Title: UBLITUXIMAB + TGR-1202 DEMONSTRATES ACTIVITY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NHL AND HIGH-RISK CLL
Presenter: Matthew Lunning, DO, University of Nebraska, Omaha, NE
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in